12:40 IST
BSE
Business UpdateGranules India Ltd GRANULES
Granules India Business Update
Granules India filed a Paragraph IV ANDA certification for Ruxolitinib ER Tablets, claiming potential 180-day U.S. generic exclusivity, subject to FDA review and confirmation.